On February 5, 2021, in connection with Urovant Sciences Ltd.'s (Company) previously disclosed debt financing agreement with Sumitomo Dainippon Pharma Co. Ltd. (Sumitomo), as lender, dated December 27, 2019 (Sumitomo Loan Agreement), Sumitomo agreed to amend the Sumitomo Loan Agreement to increase the maximum principal amount of the unsecured revolving debt financing facility from $300 million to $425 million. The proceeds of the loan will be used solely for working capital or other general corporate purposes incurred during any calendar quarter in accordance with annual budget. As previously disclosed, the Sumitomo Loan Agreement originally provided for a $300 million unsecured revolving debt financing facility, approximately $268 million of which is currently outstanding. Additional funds may be drawn down by no more than once any calendar quarter, subject to certain terms and conditions. Interest on the outstanding loans is payable quarterly, and the principal is due and payable in full on the five-year anniversary of the closing date of the Sumitomo Loan Agreement.